Physician profile
Brian Haney
NPI 1285830554
$11,960.66
in general payments reported to CMS, 2019-2025
26 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $1,766 · 2021: $76.41 · 2022: $351 · 2023: $138 · 2024: $9,082 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,880 · Food and Beverage: $637 · Education: $42.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,880.00 |
| Food and Beverage | $636.98 |
| Education | $42.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $8,977.80 | 2020-2025 | Enhertu, Injectafer |
| Exelixis INC. | $1,650.00 | 2020 | |
| Abbvie INC. | $173.02 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $147.12 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $125.60 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Amgen INC. | $115.28 | 2019-2022 | |
| Janssen Biotech, INC. | $90.03 | 2019-2023 | Darzalex, Imbruvica |
| Coherus Oncology, INC. | $89.43 | 2022 | |
| Incyte Corporation | $75.49 | 2020-2025 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $71.95 | 2019-2024 | Ninlaro |
| Pfizer INC. | $68.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $57.07 | 2019-2023 | Keytruda |
| Adc Therapeutics America, INC. | $46.76 | 2025 | |
| Genentech USA, INC. | $37.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.88 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.70 | 2024 | Ojjaara, Jemperli, Zejula |
| Dendreon Pharmaceuticals LLC | $25.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.31 | 2024 | Opdivo |
| Immunomedics, INC. | $21.04 | 2020 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Puma Biotechnology, INC. | $17.81 | 2025 | |
| Celgene Corporation | $14.90 | 2019 | |
| Eisai INC. | $13.85 | 2024 | |
| Janssen Pharmaceuticals, INC | $12.30 | 2020 | |
| Clovis Oncology, INC. | $12.25 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.